MED12 and prostate cancer: The prevalence of MED12 mutations varies considerably among different prostate cancer study cohorts. Conflicting views exist regarding the functional consequences of MED12 mutations in prostate cancer. The tumorigenic mechanisms associated with MED12 mutations may be cancer specific.